Marco leads RUBEDO driving its mission to develop treatments for age-related diseases and extend healthspan.
As a scientist, he earned a Masters degree in Biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging, Stem Cells Biology, and Regenerative Medicine in the leading lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine. He is backed by over 15 years of research with an extensive track record of scientific publications in top tier journals (such as Nature, Science, Nature Biotechnology, Cell Stem Cell). He is an inventor on U.S. patents.
As an entrepreneur, Marco first started as a PhD student, when he co-founded the international biotech umbrella organization Young European Biotech Network (YEBN) focused on international academic and industrial policies and project development. He later joined the European Federation of Biotechnology (EFB) as an executive board member along with major players from academic and biotech/pharma industry, such as Roche, Novartis and Novo Nordisk.
Quarta founded the biotech companies “WetWare Concepts” in Europe, where he served as CEO and Executive President, and “Turn Biotechnologies” in California, where he served as CSO and Director.
Quarta sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) – Calpoly program in regenerative medicine, and in the advisory and research boards at the Center for Healthcare Innovation (CHI). He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University.
Quarta keeps fostering and championing high standards of compliance, ethics and patient safety in the development of innovative translational therapeutics, putting patients and society at the center of all actions.
[scientific peer-reviewed publications: https://pubmed.ncbi.nlm.nih.gov/?term=quarta+marco]